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Abstract The number of so-called new psychoactive substances (NPS) is still increasing by 
modification of the chemical structure of known (scheduled) drugs. As analogues of 
amphetamines, 2-aminopropyl-benzofurans were sold. They were consumed because of their 
euphoric and empathogenic effects. After the 5-(2-aminopropyl)benzofurans, the 6-(2-
aminopropyl)benzofuran isomers appeared. Thus, the question arose whether the metabolic 
fate, the mass spectral fragmentation, and the detectability in urine are comparable or different 
and how an intake can be differentiated. In the present study, 6-APB (6-(2-
aminopropyl)benzofuran) and its N-methyl derivative 6-MAPB (N-methyl-6-(2-
aminopropyl)benzofuran) were investigated to answer these questions. The metabolites of 
both drugs were identified in rat urine and human liver preparations using GC-MS and/or LC-
HR-MSn. Besides the parent drug, the main metabolite of 6-APB was 4-carboxymethyl-3-
hydroxy amphetamine and the main metabolites of 6-MAPB were 6-APB (N-demethyl 
metabolite) and 4-carboxymethyl-3-hydroxy methamphetamine. The cytochrome P450 (CYP) 
isoenzymes involved in the 6-MAPB N-demethylation were CYP1A2, CYP2D6, and 
CYP3A4. An intake of a common users’ dose of 6-APB or 6-MAPB could be confirmed in rat 
urine using the authors’ GC-MS and the LC-MSn standard urine screening approaches with 
the corresponding parent drugs as major target allowing their differentiation. Furthermore, a 
differentiation of 6-APB and 6-MAPB in urine from their positional isomers 5-APB and 5-
MAPB was successfully performed after solid phase extraction and heptafluorobutyrylation 
by GC-MS via their retention times.  
 
Keywords: designer drugs; 6-APB; 6-MAPB, metabolism; GC-MS; LC-(HR)-MSn 
Page 2 of 36Analytical & Bioanalytical Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Introduction 
 
The number of so-called novel psychoactive substances (NPS) is still increasing by 
modification of the chemical structure of known (scheduled) drugs [1]. As analogues of 
amphetamines, 2-aminopropyl-benzofurans were sold since 2010. After the 5-(2-
aminopropyl)benzofurans, the 6-(2-aminopropyl)benzofuran isomers appeared. As already 
discussed [2], the benzofurans can also be seen as MDA (3,4-methylenedioxy-amphetamine) 
and MDMA (3,4-methylendioxy-methamphetamine) analogues regarding a bioisosteric 
substitution of one oxygen (-O-) in the furan ring by methine (-CH=). The MDA- and 
MDMA-like effects of these compounds have been discussed on several drug users forum on 
the Internet (e.g. www.bluelight.org; www.land-der-traeume.de) and they were used as 
stimulants or entactogens because of their euphoric and empathogenic effects. Described 
negative effects were tachycardia, jaw tensions, insomnia, and severe paranoia [3]. Acute 
psychosis together with agitation was also described in a case report where 6-APB was 
consumed together with cannabis and the synthetic cannabinoid JWH-122 [4]. Due to the 
multiple substance ingestion, it is not clear if the acute psychosis comes from 6-APB alone or 
the mixture of the ingested drugs. Nevertheless, Iversen t al. showed that 6-APB has 
inhibitory effects on the monoamine reuptake transporters with higher affinity on the 
dopamine (DA) and noradrenalin (NA) transporter and lower affinity on the serotonin (5-HT) 
transporter [5]. In addition, they showed that 6-APB acted as a full agonist at the 5-HT2B 
receptor (calcium mobilization assay) which may be relevant when considering potential 
vasoconstrictive effects and cardiotoxicity. Unfortunately, clinical studies are not available for 
6-MAPB but experience reports available on the Internet suggest that there may be 
similarities. To date, only few analytical data are available for 6-APB and 6-MAPB. Stanczuk 
et al. and Casale et al. differentiated between the several positional isomers in purchased 
products but no data are available on the differentiation between the positional isomers in 
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urine [6, 7]. Welter et al. investigated the metabolism and the detectability of the positional 
isomers 5-APB and 5-MAPB [2]. 
Thus, the question arose whether the metabolic fate, the mass spectral fragmentation, and the 
detectability in urine is comparable or different with the varied position of the alkyl chain or 
the oxygen in the ring. Another question was how an intake can be differentiated for the case 
that once the legal status might be different or if the particular drug used for homicide by 
poisoning can be found at the suspect. In the present study, 6-APB (6-(2-
aminopropyl)benzofuran) and its N-methyl derivative 6-MAPB (N-methyl-6-(2-
aminopropyl)benzofuran) were investigated to answer these questions. 
 
 
Experimental  
 
Chemicals and reagents 
 
6-APB, 5-APB, and 5-MAPB were synthesized [6] and provided by the Department of 
Pharmacology and Therapeutics, Trinity Centre for Health Sciences, St. James’s Hospital 
(Dublin, Ireland), before 5-APB and 6-APB were scheduled. 6-MAPB was synthesized and 
provided by the School of Pharmacy and Biomolecular Sciences, Liverpool John Moores 
University (Liverpool, UK). Isolute C18 (500 mg, 3 mL) and HCX cartridges (130 mg, 3 mL) 
were obtained from Biotage (Uppsala, Sweden), isocitrate and isocitrate dehydrogenase, 
heptafluorobutyric anhydride (HFBA), sodium phosphate from Sigma (Taufkirchen, 
Germany), NADP+ from Biomol (Hamburg, Germany), acetonitrile (LC-MS grade), 
ammonium formate (analytical grade), formic acid (LC-MS grade), methanol (LC-MS grade), 
mixture (100,000 Fishman units/mL) of glucuronidase (EC No. 3.2.1.31) and arylsulfatase 
(EC No. 3.1.6.1) from Helix Pomatia, and all other chemicals and reagents (analytical grade) 
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from VWR (Darmstadt, Germany). The baculovirus-infected insect cell microsomes 
(Supersomes) containing 1 nmol/mL of human cDNA-expressed CYP 1A2, CYP 2A6, CYP 
2B6, CYP 2C8, CYP 2C9, CYP 2C19, CYP 2D6, CYP 2E1 (2 nmol/mL), CYP 3A4, or CYP 
3A5 (2 nmol/mL), and pooled human liver microsomes (pHLM, 20 mg microsomal 
protein/mL, 400 pmol total CYP/mg protein) were obtained from BD Biosciences 
(Heidelberg, Germany). After delivery, the microsomes were thawed at 37°C, aliquoted, snap-
frozen in liquid nitrogen, and stored at -80°C until use.  
 
Urine samples 
 
Urine samples were used from male Wistar rats (Charles River, Sulzfeld, Germany) after 
administration of the compounds by gastric intubation using an aqueous suspension for 
toxicological diagnostic reasons according to the corresponding German law 
(http://www.gesetze-im-internet.de/tierschg/). For identification of the metabolites a single 20 
mg/kg body mass (BM) dose for 6-APB and 10 mg/kg body mass dose for 6-MAPB and for 
toxicological analysis, a single 3 mg/kg body mass dose for 6-APB or 1 mg/kg body mass 
dose for 6-MAPB were administered once. The rats were housed in metabolism cages for 24 
h, having water ad libitum. Urine was collected separately from the feces over a 24 h period. 
To check if the samples were free of interfering peaks, blank urine samples were collected 
before drug administration. The samples were directly analyzed and then stored at -20°C.  
 
Sample preparation for identification of phase I and II metabolites 
 
Urine samples were prepared as described previously [2, 8]. Briefly, urine samples were 
extracted after conjugate cleavage with a mixture of glucuronidase and arylsulfatase by solid 
phase extraction (SPE) with HCX cartridges. After elution, evaporation, and reconstitution in 
Page 5 of 36 Analytical & Bioanalytical Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
100 µL of methanol, 50 µL were left underivatized and another 50 µL were again gently 
evaporated to dryness and derivatized with a mixture of acetic anhydride and pyridine (3:2 
v/v) under microwave irradiation (450 W, 5 min). Afterwards, the residue was reconstituted in 
50 µL of methanol. A 3-µL aliquot of the extract was injected onto the GC-MS or 5 µL onto 
the LC-HR-MSn.  
For the phase II metabolism studies, 1 mL of urine was extracted with SPE (C18) cartridges. 
Analytes were eluted, evaporated, and reconstituted with 50 µL of the solvent mixture A/B 
(50:50, v/v; A: ammonia formate buffer, pH 3; B: acetonitrile/formic acid). A 5-µL aliquot of 
the extract was then injected onto the LC-HR-MSn. 
 
GC-MS apparatus for identification of the phase I metabolites 
 
For analysis of the extracts a combination of a Hewlett Packard (HP, Agilent, Waldbronn, 
Germany) 6890 Series gas chromatograph with an HP 6890 MSD mass spectrometer and an 
HP MS ChemStation (DOS series) with HP G1701AA software version A03.00 was used. 
The GC conditions were as follows: splitless injection mode; column, Optima 5 MS capillary 
(12 m x 0.2 mm I.D.), cross linked methyl silicone, 0.35 µm film thickness (Macherey-Nagel, 
Düren, Germany); injection port temperature, 280°C; carrier gas, helium; flow-rate, 0.5 
ml/min; column temperature, programmed from 85-310°C at 30°/min; initial time, 2 min; 
final time, 7 min; total time, 16 min. The MS conditions were as follows: full-scan mode, m/z 
50-550 u; electron ionization (EI) mode; ionization energy, 70 eV; ion source temperature, 
220°C; capillary direct interface, heated at 280°C.  
 
LC-HR-MSn apparatus for identification of phase I and II metabolites 
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As described previously [2, 8], a Thermo Fisher Scientific (TF) Dionex UltiMate 3000 RS 
pump consisting of a degasser, a quaternary pump and an UltiMate 3000 RS autosampler, 
coupled to a TF Orbitrap Velos Pro equipped with a heated electrospray ionization (HESI) II 
source was used for analysis of the prepared extracts. For details of the LC and MS conditions 
see ref. [8]. Briefly, a TF Hypersil Gold (C18) column (150 x 2.1 mm, 1.9 µm) with gradient 
elution with 10 mM aqueous ammonium formate buffer containing 0.1 % (v/v) formic acid as 
mobile phase A and acetonitrile containing 0.1 % (v/v) formic acid as mobile phase B was 
applied. The Orbitrap was run in the positive mode and the collision-induced dissociation 
(CID)-MS/MS experiments (normalized collision energies, 35%) were either performed in a 
data-dependent acquisition (DDA) mode (m/z 100-800) or on the following selected precursor 
ions from MS1 at m/z 218, 232, 234, 276, 278, 290, 308, 322, 336, 380, and 394 for the 
acetylated parent compounds and phase I metabolites as well as 368, 372, 386, 388, and 400 
for phase II metabolites.  
 
Microsomal incubations for initial CYP activity screening studies 
 
According to published protocols [2, 8], each isomer was incubated. Briefly, incubation with 
the CYP isoenzymes (50 pmol/mL, each) CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, 
CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5 or HLM (1 mg protein/mL) was 
performed at 150 µmol/L substrate concentration. After 30 min, the reaction was stopped with 
ice-cold acetonitrile, centrifuged and the supernatant transferred to an autosampler vial, 
afterwards 5 µL were injected onto the LC-HR-MSn.  
 
LC-HR-MSn apparatus for analysis of the microsomal incubation 
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For the analysis of the incubations the same system was used as described for the metabolism 
studies with the following modifications: CID-MS/MS experiments were performed either in 
the DDA mode or on the precursor ions from MS1 for 6-APB, hydroxy, hydroxy-dihydro, 4-
carboxymethyl-3-hydroxy amphetamine (m/z 176.1069, 192.1019, 194.1175, 210.1124) or 6-
MAPB, N-demethyl, hydroxy, hydroxy-dihydro, and 4-carboxymethyl-3-hydroxy 
methamphetamine (m/z 176.10169, 190.1226, 206.1175, 208.1332, 224.1281). For calculation 
of the relative amount of metabolites formed during incubations the peak areas were used 
determined with TF Xcalibur Qual Browser software version 2.2 SP1.48.  
 
GC-MS standard urine screening approach (SUSA) 
 
As published before [2, 9, 10], the sample preparation procedure consisted of acid hydrolysis 
for fast conjugate cleavage and extraction with a dichloromethane-isopropanol-ethyl acetate 
mixture (1:1:3 v/v/v). After evaporation, the residue was acetylated with an acetic anhydride-
pyridine mixture under microwave irradiation (450 W, 5 min), again evaporated and 
reconstituted in 100 µL of methanol. The GC and MS conditions for analysis of the extracts 
were the same as described above for the metabolism studies.  
For toxicological detection, mass chromatography was used with the extracted ions at m/z 58, 
86, 100, 131, 147, 160, 163, 174, 190, 206, 218, and 220 for the acetylated 6-APB, 6-MAPB, 
and their metabolites. Confirmation of the peak identity in the mass chromatograms was 
performed by computerized comparison of the mass spectra underlying the peaks (after 
background subtraction) with reference spectra recorded during this study. The automated 
mass spectral deconvolution and identification system (AMDIS) 
(http://chemdata.nist.gov/mass-spc/amdis/) was also used for evaluation of the full scan data 
files acquired by the GC-MS system, as described previously [11]. 
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LC-MSn standard urine screening approach 
 
The urine samples (100 µL) were diluted with acetonitrile, shaken, centrifuged, evaporated to 
dryness, and reconstituted in mobile phase A/B (v/v; 50:50) as described elsewhere [2, 12]. 
The samples were analyzed using a TF LXQ linear ion trap MS equipped with an HESI II 
source and coupled to a TF Accela LC system. The LC conditions were as described for LC-
HR-MSn and the MS settings are described elsewhere [2, 12]. In brief, data-dependent 
acquisition (DDA) was performed on precursor ions selected from MS1: MS1 was performed 
in the full scan mode (m/z 100-800). MS2 and MS3 were performed in the DDA mode: four 
DDA MS2 scan filters and eight MS3 scan filters were chosen to provide MS2 on the four most 
intense signals from MS1 and MS3 on the most and second most intense signals from the MS2.  
 
Sample preparation and apparatus for differentiation of the isomers by GC-MS 
 
Blank urine samples were spiked with each of the isomers (5-APB, 6-APB, 5-MAPB and 6-
MAPB) in a final concentration of 100 µg/L. The spiked urine samples or the rat urines after 
administration of the low doses of 5-APB, 6-APB, 5-MAPB, or 6-MAPB were worked up by 
conjugates cleavage followed by solid phase extraction with an HCX cartridge as described 
above but with HFBA derivatization according to Peters et al. [13]. Afterwards, 3 µL of the 
extracts were analyzed with the GC-MS apparatus described above but with the following 
modifications: column, Optima 5 MS capillary (25 m x 0.2 mm I.D.), 0.35 µm film thickness 
(Macherey-Nagel, Düren, Germany); column temperature, programmed from 80-200°C at 
5°C/min, 2 min hold, 200-310°C at 35°C/min; initial time, 2 min; final time, 3 min; total time, 
34 min; carrier gas, helium; flow-rate, 0.8 ml/min.  
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Results and discussion 
 
The metabolites were identified in rat urine samples after administration of doses that 
corresponded to the doses reported for multiple and/or higher dosing scaled by dose-by-factor 
approach according to Sharma et al. [14]. The different workup procedures were used as for 
the 5-isomers. Preliminary tests with the parent drugs showed that their efficiencies were 
comparable (data not shown). 
 
GC-MS identification of phase I metabolites  
 
Metabolite structures were elucidated by interpreting the fragments in the EI spectra of the 
metabolites in correlation to that of the parent compound. The fragmentation patterns of other 
amphetamines and furan or benzofuran containing compounds [2, 6, 15-22] as well as the 
general fragmentation rules described by e.g. Smith and Bush or McLafferty were taken into 
consideration [23, 24]. Furthermore, published data on the metabolism of 5-APB and 5-
MAPB were considered [2]. Figure 1 shows the EI mass spectra, structures, predominant 
fragmentation patterns, and GC retention indices (RI) of the acetylated parent compounds and 
their acetylated metabolites (1–10). These reference data are essential for identification of 
these drugs in any GC-MS laboratory.  
 
EI-MS fragmentation of the phase I metabolites 
 
Below, important fragmentation patterns of the EI mass spectra of acetylated 6-APB and 6-
MAPB and their metabolites will be discussed in depth allowing postulation of the structures 
depicted in Fig. 1.1 – 1.10. The numbers of the corresponding mass spectra are given in 
brackets. 6-APB and most of its metabolites were also the corresponding N-demethyl 
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metabolites of 6-MAPB, this is in accordance to published data about 5-APB and 5-MAPB 
[2]. The EI fragmentation of the 6-isomer metabolites was often the same as described for the 
corresponding 5-isomer metabolites (e.g. 1-5), therefore, only the spectra with differences 
were described in depth. The spectrum of twofold acetylated hydroxy 6-MAPB (6) showed 
the fragment ions at m/z 58 and 100 typical for methamphetamine derivatives and resulting 
from a cleavage between position 1 and 2 in the propylamine side chain. The fragment ions at 
m/z 174 and 216 resulted from the cleavage of N-methyl-acetamide (73 u) and a following 
loss of the second acetyl group (42 u). The spectra of three fold acetylated 4-hydroxyethyl-3-
hydroxy amphetamine/N-demethyl-4-hydroxyethyl-3-hydroxy methamphetamine (7) and 4-
hydroxyethyl-3-hydroxy methamphetamine (9) showed fragment ions either at m/z 86 or 58 
and 100 for the primary amine or the secondary amine, respectively. Cleavage of acetamide 
(59 u) or N-methyl-acetamide from the precursor ions, respectively, lead to fragment ion at 
m/z 262, a following loss of acetic acid (60 u) then lead to fragment ion at m/z 202, and a 
subsequent loss of another acetyl group lead to fragment ion at m/z 160. Spectrum no. 10, 
threefold acetylated 4-dihydroxy-3-hydroxy amphetamine/N-demethyl-4-dihydroxy-3-
hydroxy methamphetamine –H2O (10), was an artifact most likely formed in the GC injection 
port. A loss of water is often described when a hydroxy group is located at a side chain, 
therefore this artifact derived most probably from 4-dihydroxy-3-hydroxy amphetamine/N-
demethyl-4-dihydroxy-3-hydroxy methamphetamine. The spectrum showed fragment ions at 
260 after the loss of acetamide, a following stepwise loss of two acetyl groups lead to 
fragment ions at m/z 218 and 176, respectively. As can be seen in Figure 1, for both 
compounds, ring opened metabolites could be observed as already described for 5-APB, 5-
MAPB and other benzofuran containing compounds. The corresponding mechanism has been 
described by Kobayashi et al. and Connelly et al. [17, 18]. They could show that the ring 
cleavage occurs via an unsaturated aldehyde and leads to either an alcohol or the carboxylic 
acid by reduction or oxidation of the intermediate. In summary, there are only small 
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differences in the fragmentation of the 6-isomers compared to the 5-isomers and by 
comparing only the spectra of the metabolites mass spectral differentiation was not possible. 
 
LC-HR-MSn fragmentation and identification of phase I metabolites 
 
The fragmentation of 6-APB, 6-MAPB and their metabolites detected by LC-HR-MSn will be 
explained in detail according to the fragments given in Table 1. All metabolites identified by 
GC-MS could be confirmed with the exception of hydroxy-deamino-dihydro 6-APB/hydroxy-
deamino-dihydro 6-MAPB most probably because of poor ionization with the chosen 
ionization mode due to the loss of the nitrogen moiety. Three additional metabolites could be 
detected, namely dihydro 6-MAPB (11), hydroxy-dihydro 6-APB/N-demethyl-hydroxy-
dihydro 6-MAPB (12), and 4-dihydroxyethyl-3-hydroxy methamphetamine (13) most likely 
due to the higher sensitivity of the LC-HR-MSn system. As already seen for 5-APB and other 
amines [2, 8], underivatized 6-APB formed only few fragments. Therefore, all HR spectra 
were recorded in urine extracts after acetylation resulting in more specific MS2 and MS3 
spectra. In Table 1, all identified acetylated phase I metabolites of 6-APB and 6-MAPB are 
listed together with the accurate and the calculated exact masses, the corresponding two main 
fragment ions in MS2 and the two most abundant fragment ion in the corresponding MS3 
spectra, if available, the elemental compositions, the deviations of the measured accurate 
masses from the calculated masses, given as errors in ppm (all within 5 ppm deviation), and 
the retention times.  
The fragmentation of 6-APB, 6-MAPB and their metabolites will be explained in detail 
according to the fragments given in Table 1. The MS2 spectrum of underivatized 6-APB (1a; 
protonated molecular mass, PM, at m/z 176.1064) showed two fragment ions, the 
benzofuranyl-methylium ion at m/z 131.0492 resulting from an alpha cleavage and the 
fragment ion at m/z 117.0699 resulting from loss of oxygen most likely followed by a 
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rearrangement of the ring. Acetylation resulted in more specific spectra due to the formation 
of more fragment ions. After derivatization the MS2 spectrum of 6-APB (1b; PM at m/z 
218.1167) showed fragment ions at m/z 159.0805 and 176.1072, resulting from the loss of the 
acetyl group (42.0105 u) and a following loss of ammonia (17.0265 u). Detected fragments in 
the MS3 spectra were at m/z 131.0492 and 117.0699, which could also be observed in the 
spectrum of underivatized 6-APB. Underivatized 6-MAPB (2a, PM at m/z 190.1220) formed 
more fragments; nevertheless the acetylated extracts were also used. Acetylated 6-MAPB (2b; 
PM at m/z 232.1321) showed fragment ions at m/z 190.1228 after loss of the acetyl group and 
159.0805 for the benzofuranyl-propylium ion. The MS2 of two fold acetylated hydroxy 6-
APB/N-demethyl-hydroxy 6-MAPB (4; PM at m/z 276.1223) and of two fold acetylated 
hydroxy 6-MAPB (6; PM at m/z 290.1376) showed fragment ions at m/z 217.0860 after loss 
of acetamide (59.0371 u) and N-methyl-acetamide (73.0527 u), respectively or fragment ions 
at m/z 234.1126 or 248.1282 after an alternative loss of only the acetyl group. The MS3 
spectra showed fragment ions at m/z 175.0755, resulting from the loss of the second acetyl 
group from ion at m/z 217 and representing the hydroxy-benzofuranyl-propylium ion (shift of 
16 u from m/z 159). The acetoxy-benzofuranyl-methylium ion at m/z 189.0548 resulted from 
alpha cleavage. The MS2 spectrum of the methylester of two fold acetylated 4-carboxymethyl-
3-hydroxy amphetamine/N-demethyl-4-carboxymethyl-3-hydroxy methamphetamine (5; PM 
at m/z 308.1480) showed fragment ions at m/z 266.1385 (loss of one acetyl group) and 
234.1127 (following loss of methanol m/z 32.0262 from the ester). In the MS3 spectra, the 
fragment ion at m/z 224.1286 was present, resulting from the loss of the second acetyl group 
and representing the methylester of 4-carboxymethyl-3-hydroxy amphetamine. Fragment ions 
at m/z 192.1014 and 175.0755 resulted from cleavage of one acetyl group from fragment at 
m/z 234.1125 and subsequent loss of ammonia. The spectrum of 4-carboxymethyl-3-hydroxy 
methamphetamine (8; PM at m/z 322.1637) showed fragment ions at m/z 280.1543 and 
238.1441 resulting from the consecutive loss of two acetyl groups and leading to the 
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methylester of 4-carboxymethyl-3-hydroxy methamphetamine. In the MS3 of 280, fragment 
ions were observed at m/z 238.1437 and 207.1016 resulting from either the loss of one acetyl 
group or of N-methyl-acetamide. The MS2 spectrum of three fold acetylated 4-hydroxyethyl-
3-hydroxy amphetamine/N-demethyl-4-hydroxyethyl-3-hydroxy methamphetamine (7; PM at 
m/z 322.1639) showed fragment ions at m/z 280.1543 resulting from loss of one acetyl group 
and fragment ion at m/z 220.1335 indicating the hydroxy group at the alkyl chain because of 
the loss of acetic acid (60.0211 u) from m/z 280.1543. The most abundant fragment ions in the 
MS3 spectra were generated by loss of one acetyl group followed by loss of water from 
fragment at m/z 280.1543 resulting in fragment ions at m/z 238.1438 and 220.1333. Fragment 
ions at m/z 178.1227 and 161.0961 represent either the 4-hydroxy-3-vinylphenyl-
propanaminium or the 4-hydroxy-3-vinylphenyl-propylium ion resulting from consecutive 
loss of one acetyl group and ammonia. The MS2 spectrum of three fold acetylated 4-
hydroxyethyl-3-hydroxy methamphetamine (9; PM at m/z 336.1794) showed fragment ions at 
m/z 294.1699 and 252.1594, resulting from consecutive loss of two acetyl groups. The 
corresponding MS3 spectra showed fragment ions at m/z 179.1065, resulting from loss of N-
methyl-acetamide and after loss of ammonia fragment ion at m/z 161.0960. Four fold 
acetylated 4-dihydroxyethyl-3-hydroxy amphetamine/N-demethyl-4-dihydroxyethyl-3-
hydroxy methamphetamine (10; PM at m/z 380.1691) showed in the MS2 spectrum as most 
abundant fragment ions those at m/z 320.1491 resulting from loss of acetic acid indicating a 
hydroxy group in the side chain and at m/z 278.1378, from a subsequent loss of one acetyl 
group. The MS3 spectrum of fragment ion at m/z 320.1491 showed ions at m/z 278.1385 and 
236.1281 resulting from the loss of two acetyl groups. The most abundant fragments in the 
MS2 spectrum of acetylated dihydro 6-MAPB (11; PM at m/z 234.1484) were at m/z 161.0960 
resulting from the loss of N-methyl-acetamide and at m/z 133.0648 after a following loss of 
ethylene (28.0313 u), representing either the dihydro-benzofuranyl-propylium or the dihydro-
benzofuranyl-methylium ion. Fragment ions at m/z 236.1280 and 218.1174 were present in 
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the MS2 spectrum of two fold acetylated hydroxy-dihydro 6-APB/ N-demethyl-hydroxy-
dihydro 6-MAPB (12; PM at m/z 278.1378), resulting from the loss of one acetyl group 
followed by the loss of water (18.1015 u). Fragments at m/z 177.0909 and 159.0803 were 
present in the MS3 spectrum of fragment ion at m/z 236 representing the hydroxy-dihydro-
benzofuranyl-propylium ion and after loss of water the corresponding benzofuranyl-
propylium ion. Four fold acetylated hydroxy-dihydro 6-MAPB (13; PM at m/z 394.1846) 
showed fragment ion at m/z 334.1645, resulting from loss of acetic acid and at m/z 292.1540 
after a subsequent loss of one acetyl group. The MS3 spectra of m/z 334 showed fragment ions 
at m/z 292.1539 and 261.1119, resulting from loss of one acetyl group and a subsequent loss 
of methanamine (31.0421 u). 
The fragmentation patterns were similar to those described for 5-APB and 5-MAPB, but those 
of the ring-opened metabolites showed some differences, maybe due to the position of the 
oxygen and the alkyl chain after ring opening. The meta-position of the oxygen and the side 
chain for the 6-isomers might lead to a different fragmentation pattern than the para-position, 
due to different mesomeric and inductive effects. 
 
LC-HR-MSn fragmentation and identification of the phase II metabolites 
 
For the identification of glucuronides and/or sulfates, two different modes were used, either 
data-dependent scan mode with a parent mass list containing the precursor ions calculated 
from those of the corresponding phase I metabolites or by searching for a specific neutral loss 
of 176.0320 u for glucuronides and/or 79.9568 u for sulfates. For identification, the MS3 
spectra of the detected glucuronides were, if possible, compared with the MS2 spectra of the 
corresponding phase I metabolites. Unfortunately no MS3 spectra could be detected most 
probably due to small formation rates. In Table 2, all identified phase II metabolites are listed 
together with the accurate and the calculated exact masses, the corresponding two main 
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fragment ions in MS2 spectra, the corresponding elemental compositions, the deviations of the 
measured accurate masses from the calculated masses, given as errors in ppm (all within 5 
ppm deviation), and the retention times.  
In accordance to the 5-isomers, no sulfates could be observed, but the following glucuronides: 
4-carboxymethyl-3-hydroxy amphetamine glucuronide (5G), 4-hydroxyethyl-3-hydroxy 
amphetamine glucuronide (7G), and 4-dihydroxyethyl-3-hydroxy amphetamine glucuronide 
(10G). For 6-MAPB, N-demethyl-4-carboxymethyl-3-hydroxy methamphetamine glucuronide 
(5G), 4-carboxymethyl-3-hydroxy methamphetamine glucuronide (8G), N-demethyl-4-
hydroxyethyl-3-hydroxy methamphetamine glucuronide (7G), 4-hydroxyethyl-3-hydroxy 
methamphetamine glucuronide (9G), and N-demethyl-4-dihydroxy-3-hydroxy 
methamphetamine glucuronide. In addition, hydroxy-aryl 6-APB glucuronide (4G) could be 
detected. 
In summary, most MS2 spectra recorded after a neutral loss of 176 u showed the accurate 
mass of the corresponding phase I metabolites and the accurate mass after loss of ammonia or 
methanamine. For example, the hydroxy-aryl 6-APB glucuronide (4G; PM at m/z 368.1348) 
showed in MS2 most abundant fragment ions at m/z 192.1014 and m/z 175.0749, representing 
the phase I metabolite and after loss of ammonia or methanamine the hydroxy-benzofuranyl-
propylium ion. For 4-carboxymethyl-3-hydroxy amphetamine/N-demethyl-4-carboxymethyl-
3-hydroxy methamphetamine glucuronide (5G; PM at m/z 386.1430) and 4-hydroxyethyl-3-
hydroxy amphetamine/N-demethyl 4-hydroxyethyl-3-hydroxy methamphetamine glucuronide 
(7G; PM at m/z 372.1636) the previously described fragmentation pattern was observed. 4-
Hydroxyethyl-3-hydroxy methamphetamine (9G; PM at m/z 386.1787) showed most 
abundant fragment ions in MS2 at m/z 210.1484 representing the corresponding phase I 
metabolite and at m/z 179.1062 resulting from the loss of methanamine. 4-Carboxymethyl-3-
hydroxy methamphetamine glucuronide (8G; PM at m/z 400.1595) showed a different 
fragment pattern by ions at m/z 224.1276, after loss of the conjugate, and at m/z 206.1171 
Page 16 of 36Analytical & Bioanalytical Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
after loss of water from the carboxy group. This loss of water has been described before [25]. 
The spectrum of 4-dihydroxyethyl-3-hydroxy amphetamine/N-demethyl-4-dihydroxyethyl-3-
hydroxy methamphetamine glucuronide (10G; PM at m/z 388.1602) was the only one where 
the fragment for the corresponding phase I metabolite was not one of the most abundant ones. 
The most abundant fragments present in this spectrum were at m/z 195.1010 and 177.0905. 
Fragment at m/z 195.1010 resulted from loss of the conjugate and a subsequent loss of 
ammonia and a following loss of water then lead to fragment ion at m/z 177.0905.  
 
Proposed metabolic pathways 
 
The main metabolic pathways for 6-APB and 6-MAPB proposed according to the identified 
metabolites are summarized in Fig. 2. They were in accordance to those of 5-APB and 5-
MAPB as well as of furan and benzofuran [2, 17, 18, 21]. Hydroxylation of 6-APB (1) at the 
furan ring (4) was the initial step. The following ring cleavage and reduction of the resulting 
unsaturated aldehyde lead to the corresponding aldehyde, which was either oxidized to the 
corresponding carboxylic acid (5) or reduced to the alcohol (7). The alcohol was further 
hydroxylated (10) and this one as well as the carboxylic acid and alcohol, were 
glucuronidated (5G, 7G, 10G). Hydrogenation of the hydroxy metabolite could also be 
observed (12), as well as deamination followed by reduction (3). For 6-MAPB (2), the 
predominant step was N-demethylation to 6-APB (1), which underwent the same pathways as 
described for 6-APB. 6-MAPB itself also underwent most of the described pathways, namely 
benzofuran hydroxylation (6) followed by enzymatic ring cleavage to either an alcohol (9) by 
reduction or carboxylic acid (8) by oxidation of the intermediate aldehyde. The alcohol was 
further hydroxylated (13) and both carboxylic acid and alcohol were glucuronidated (8G, 9G). 
A further pathway was hydrogenation (11) of 6-MAPB. In summary, N-demethylation was 
the predominant step due to the corresponding relative GC-MS and LC-MS peak areas for 6-
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MAPB. Enzymatic cleavage of the benzofuran ring was another step and the most important 
step for 6-APB, finally leading to the corresponding carboxy or hydroxy metabolite by 
oxidation or reduction.  
All together there were not much differences between the metabolites formed for 6-APB, 6-
MAPB compared to the corresponding 5-isomers. Slight differences could be observed in the 
formation of dihydroxy metabolites, which could be detected only for the 5-isomers. 
Additional metabolites detected only for the 6-isomers were dihydro 6-MAPB (11) and the 
glucuronide of 4-dihydroxyethyl-3-hydroxy amphetamine/N-demethyl-4-dihydroxyethyl-3-
hydroxy methamphetamine (10G). These differences might be caused by lower formation 
rates due to different affinity of the meta-position of the oxygen in the 6-isomers to the active 
center of the involved enzymes in contrast to the para-position of the 5-isomers and/or by 
different elimination rates.  
 
HLM incubations and initial CYP activity screening 
 
The drugs were incubated with HLM to see whether the humans form in principle the same 
metabolites as the rat. Unfortunately, for 6-APB no metabolites could be detected in HLM 
incubations and for 6-MAPB only N-demethyl 6-MAPB (1) could be found. This is more or 
less in accordance to the low dose rat urine results, where the N-demethyl 6-MAPB was the 
only metabolite detected with the GC-MS approach and the case report of Chan et al. [4], 
where only 6-APB could be detected. Again, the difference to the 5-isomers, for which 
several metabolites could be detected [2], might be caused by different affinity to the 
catalyzing enzymes. 
The initial CYP activity screening [2] was not possible for 6-APB due to the very low 
metabolite formation rate maybe caused by the CYP inhibition potential of such benzofuran 
designer drugs [26]. Only the N-demethylation of 6-MAPB could be monitored. The enzymes 
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involved in this step were CYP1A2, CYP2D6, and CYP3A4. CYP enzyme kinetics could not 
be performed due to the low metabolite formation rates. 
 
Toxicological detection of 6-APB and 6-MAPB by GC-MS or LC-MSn 
 
Application of the compounds could be monitored in rat urine after administration of 3 mg/kg 
BM 6-APB or 1 mg/kg BM 6-MAPB, respectively, using the GC-MS-based SUSA described 
by the authors [8, 9]. The used low doses corresponded to reported human single doses of 
about 30 mg for 6-APB or 10 mg for 6-MAPB scaled by dose-by-factor approach according 
to Sharma et al. [14]. Therefore, detection of the intake of these compounds should be 
possible also in human urine. The possible presence of 6-APB or 6-MAPB and their 
metabolites, within the GC-MS SUSA, were indicated by reconstructed mass chromatography 
with the ions at m/z 86, 100, 131, 147, 190, and 206 for the acetylated parent compounds and 
their metabolites according to the corresponding reference spectra given in Fig. 1. Figure 3 
shows reconstructed ion chromatograms after a low dose of 6-APB (Fig. 3A) and 6-MAPB 
(3B). As can be seen, the main excretion products were 6-APB and 6-MAPB themselves, 
whereas for 6-MAPB also the N-demethyl metabolite could be detected with the GC-MS 
SUSA. Furthermore, the microsomal incubations with HLM showed that N-demethyl 6-
MAPB was the only metabolite detectable, which was in accordance to the in vivo results 
from the rat studies. This supports the assumption that the approach should be suitable for 
drug testing even in human urine. In addition, Welter et al. [2] showed that N-demethyl 5-
MAPB was the main metabolite in rat and in human urine, indicating that this might also be 
true for 6-MAPB. The other identified metabolites may also occur in human urine in case of 
severe overdoses and/or genetic variations of metabolisms (as well as species differences,) 
and should therefore be included in the mass ion chromatograms. Confirmation of the peak 
identity indicated by the selected mass chromatogram was performed by computerized 
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comparison of the underlying full scan mass spectrum with reference spectra recorded during 
this study. Additionally, evaluation of the full scan data files acquired by GC-MS was done by 
AMDIS allowing the detection of 6-APB and 6-MAPB in the prepared urine samples using 
the previously described procedure [11]. 
With the LC-MSn SUSA [27], the main excretion products detected in low dose rat urine were 
again 6-APB and 6-MAPB. As can be seen in Fig. 3, it was also possible to detect 4-
carboxymethy-3-hydroxy amphetamine in the low dose 6-APB rat urine (Fig. 3C) as well as 
N-demethyl 6-MAPB, 4-carboxymethyl-3-hydroxy amphetamine, and N-demethyl-4-
carboxymethy-3-hydroxy methamphetamine in the low dose 6-MAPB rat urine (3D). As 
indicated by Table 1, the respective parent compounds did not show characteristic 
fragmentations without prior acetylation. Nevertheless, it was possible to confirm the intake 
of 6-APB and 6-MAPB via the spectra and retention times of the unchanged drugs and the 
detected metabolites. Table 3 summarizes the detected metabolites together with their PMs 
and the corresponding two main fragments in MS2 and MS3, if available.  
 
Analytical differentiation of 5-APB, 6-APB, 5-MAPB, and 6-MAPB by GC-MS 
 
For the case, that the isomers must be differentiated, both SUSAs were not suitable due to 
very similar chromatographic properties. Thus, another sample work-up was tested according 
to Peters et al. [13]. Figure 4A shows a reconstructed ion chromatogram of a mixture of the 
positional isomers 5-APB, 6-APB, 5-MAPB, and 6-MAPB in a pure compound solution 
(concentration 100 µg/L, each) without extraction but analyzed with the GC-MS method 
described for differentiation of isomers. The observed elution order for the HFB derivatized 
compounds was as follows: 5-APB < 6-APB <5-MAPB < 6-MAPB. This elution order for 
APBs in pure compound solutions after heptafluorobutyrylation has already been described by 
Stanczuk et al. [6]. Figure 4B shows reconstructed ion chromatograms of a mixture of 
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prepared low dose rat urine samples. Each isomer could be detected at the expected retention 
time even in matrix. The spectra of the HFB derivatives are shown in Figure 4C. As can be 
seen, the spectra for the respective positional isomers are very similar, and therefore also not 
suitable for differentiation.  
 
 
Conclusions 
 
6-APB and 6-MAPB were metabolized only to a minor extent in rats. CYP1A2, CYP2D6, 
and CYP3A4 mainly catalyze the N-demethylation of 6-MAPB. An intake of the compounds 
in urine could be proved by both SUSAs tested, focusing on the detection of the parent drugs 
and the N-demethyl 6-MAPB. Intake of the 6-isomers from that of the 5-isomers in urine 
could be differentiated by GC-MS after heptafluorobutyrylation providing different retention 
times.  
 
Acknowledgements 
The authors like to thank Achim Caspar, Julia Dinger, Andreas Helfer, Julian Michely, Carina 
Wink, Gabriele Ulrich, Carsten Schröder, and Armin A. Weber for support and/or helpful 
discussion. 
Page 21 of 36 Analytical & Bioanalytical Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
References 
 1.  European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2014) 
European Drug Report: Trends and developments. 
http://www.emcdda.europa.eu/attachements.cfm/att_228272_EN_TDAT14001ENN.
pdf  
 2.  Welter J, Kavanagh P, Meyer MR, Maurer HH (2015) Benzofuran analogues of 
amphetamine and methamphetamine: Studies on the metabolism and toxicological 
analysis of 5-APB and 5-MAPB in urine and plasma using GC-MS and LC-(HR)-
MSn techniques. Anal Bioanal Chem, DOI: 10.1007/s00216-014-8360-0 
 3.  Advisory Council on the Misuse of Drugs (ACMD) (2013) Benzofurans: A review of 
the evidence of use and harm. 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/26178
3/Benzofuran_compounds_report.pdf  
 4.  Chan WL, Wood DM, Hudson S, Dargan PI (2013) Acute psychosis associated with 
recreational use of benzofuran 6-(2-aminopropyl)benzofuran (6-APB) and cannabis. 
J Med Toxicol 9:278-281 
 5.  Iversen L, Gibbons S, Treble R, Setola V, Huang XP, Roth BL (2013) Neurochemical 
profiles of some novel psychoactive substances. Eur J Pharmacol 700:147-151 
 6.  Stanczuk A, Morris N, Gardner EA, Kavanagh P (2013) Identification of (2-
aminopropyl)benzofuran (APB) phenyl ring positional isomers in internet purchased 
products. Drug Test Anal 5:270-276 
 7.  Casale JF, Hays PA (2012) The Characterization of 6-(2-Aminopropyl)benzofuran and 
Differentiation from its 4-, 5-, and 7-Positional Analogues. Microgram J 9:61-74 
 8.  Welter J, Meyer MR, Wolf E, Weinmann W, Kavanagh P, Maurer HH (2013) 2-
Methiopropamine, a thiophene analogue of methamphetamine: Studies on its 
Page 22 of 36Analytical & Bioanalytical Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
metabolism and detectability in the rat and human using GC-MS and LC-(HR)-MS 
techniques. Anal Bioanal Chem 405:3125-3135 
 9.  Maurer HH, Pfleger K, Weber AA (2011) Mass Spectral and GC Data of Drugs, 
Poisons, Pesticides, Pollutants and their Metabolites. Wiley-VCH, Weinheim 
(Germany) 
 10.  Ewald AH, Ehlers D, Maurer HH (2008) Metabolism and toxicological detection of 
the designer drug 4-chloro-2,5-dimethoxyamphetamine in rat urine using gas 
chromatography-mass spectrometry. Anal Bioanal Chem 390:1837-1842 
 11.  Meyer MR, Peters FT, Maurer HH (2010) Automated mass spectral deconvolution and 
identification system for GC-MS screening for drugs, poisons, and metabolites in 
urine. Clin Chem 56:575-584 
 12.  Wissenbach DK, Meyer MR, Remane D, Weber AA, Maurer HH (2011) Development 
of the first metabolite-based LC-MSn urine drug screening procedure - exemplified 
for antidepressants. Anal Bioanal Chem 400:79-88 
 13.  Peters FT, Schaefer S, Staack RF, Kraemer T, Maurer HH (2003) Screening for and 
validated quantification of amphetamines and of amphetamine- and piperazine-
derived designer drugs in human blood plasma by gas chromatography/mass 
spectrometry. J Mass Spectrom 38:659-676 
 14.  Sharma V, McNeill JH (2009) To scale or not to scale: the principles of dose 
extrapolation. Br J Pharmacol 157:907-921 
 15.  Dalvie DK, Kalgutkar AS, Khojasteh-Bakht SC, Obach RS, O'Donnell JP (2002) 
Biotransformation reactions of five-membered aromatic heterocyclic rings. Chemical 
Research in Toxicology 15:269-299 
 16.  Meyer MR, Vollmar C, Schwaninger AE, Maurer HH (2012) New cathinone-derived 
designer drugs 3-bromomethcathinone and 3-fluoromethcathinone: studies on their 
Page 23 of 36 Analytical & Bioanalytical Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
metabolism in rat urine and human liver microsomes using GC-MS and LC-high-
resolution MS and their detectability in urine. J Mass Spectrom 47:253-262 
 17.  Connelly JC, Connor SC, Monte S, Bailey NJ, Borgeaud N, Holmes E, Troke J, 
Nicholson JK, Gavaghan CL (2002) Application of directly coupled high 
performance liquid chromatography-NMR-mass spectometry and 1H NMR 
spectroscopic studies to the investigation of 2,3-benzofuran metabolism in Sprague-
Dawley rats. Drug Metab Dispos 30:1357-1363 
 18.  Kobayashi T, Sugihara J, Harigaya S (1987) Mechanism of metabolic cleavage of a 
furan ring. Drug Metab Dispos 15:877-881 
 19.  Le Fur JM, Labaune JP (1985) Metabolic pathway by cleavage of a furan ring. 
Xenobiotica 15:567-577 
 20.  Renzulli C, Nash M, Wright M, Thomas S, Zamuner S, Pellegatti M, Bettica P, Boyle 
G (2011) Disposition and metabolism of [14C]SB-649868, an orexin 1 and 2 
receptor antagonist, in humans. Drug Metab Dispos 39:215-227 
 21.  Ravindranath V, Burka LT, Boyd MR (1984) Reactive metabolites from the 
bioactivation of toxic methylfurans. Science 224:884-886 
 22.  Ou T, Tatsumi K, Yoshimura H (1977) Isolation and identification of urinary 
metabolites of AF-2 (3-(5-nitro-2-furyl)-2-(2-furyl)acrylamide) in rabbits. Biochem 
Biophys Res Commun 75:401-405 
 23.  McLafferty FW, Turecek F (1993) Interpretation of Mass Spectra. University Science 
Books, Mill Valley CA 
 24.  Smith RM, Busch KL (1999) Understanding Mass Spectra - A Basic Approach. 
Wiley, New York NY 
 25.  Helfer AG, Turcant A, Boels D, Ferec S, Lelievre B, Welter J, Meyer MR, Maurer HH 
(2014) Elucidation of the metabolites of the novel psychoactive substance 4-methyl-
N-ethyl-cathinone (4-MEC) in human urine and pooled liver microsomes by GC-MS 
Page 24 of 36Analytical & Bioanalytical Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
and LC-HR-MS/MS techniques and of its detectability by GC-MS or LC-MSn 
standard screening approaches. Drug Test Anal, DOI 10.1002/dta.1682 
 26.  Dinger J, Meyer MR, Maurer HH (2014) In vitro cytochrome P450 inhibition potential 
of methylenedioxy-derived designer drugs studied with a two cocktail approach. 
Arch Toxicol, DOI: 10.1007/s00204-014-1412-6 
 27.  Wissenbach DK, Meyer MR, Remane D, Philipp AA, Weber AA, Maurer HH (2011) 
Drugs of abuse screening in urine as part of a metabolite-based LC-MS(n) screening 
concept. Anal Bioanal Chem 400:3481-3489 
 
 
  
Page 25 of 36 Analytical & Bioanalytical Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Table 1 List of 6-APB, 6-MAPB, and all acetylated phase I metabolites together with the 
accurate and the exact masses of their PM recorded in MS1, the corresponding main fragment 
ions in MS2 and MS3, the corresponding elemental compositions, the deviations of the 
measured accurate masses from the calculated masses, given as errors in ppm, and the 
retention times 
 
No. Metabolites and characteristic ions  
Measured accurate masses [u] 
 
Calculated exact masses 
[u] 
Elemental composition 
 
Error 
[ppm] 
RT 
[min] 
1a 6-APB  
6-MAPB-M (N-demethyl-) 
 
 
 
 
5.1 MS1 PM at m/z 176.1064 176.1069 C11H14NO -3.09 
MS2 fragment ion at m/z 131.0492 
fragment ion at m/z 117.0699 
131.0491 
117.0698 
C9H7O 
C9H9 
0.10 
0.20 
MS3 n.d. 
 
   
1b 6-APB AC 
6-MAPB-M (N-demethyl-) AC 
 
 
 
 
 
 
10.8 
MS1 PM at m/z 218.1167 218.1175 C13H16NO2 -4.15 
MS2 fragment ion at m/z 159.0805 
fragment ion at m/z 176.1072 
159.0804 
176.1069 
C11H11O 
C11H14NO 
0.62 
1.08 
MS3 on 159 fragment ion at m/z 131.0491 
fragment ion at m/z 117.0700 
131.0491 
117.0698 
 
C9H7O 
C9H9 
 
0.52 
0.65 
 
MS3 on 176 fragment ion at m/z 131.0491 
fragment ion at m/z 117.0699 
131.0491 
117.0698 
 
C9H7O 
C9H9 
 
0.05 
0.20 
       
2a 6-MAPB  
 
 
 
 
5.8 
MS1 PM at m/z 190.1220 190.1226 C12H16NO -3.37 
MS2 fragment ion at m/z 159.0805 
fragment ion at m/z 131.0493 
159.0804 
131.0491 
C11H11O 
C9H7O 
0.40 
0.81 
MS3 on 159 fragment ion at m/z 131.0491 
fragment ion at m/z 117.0699 
 
131.0491 
117.0698 
C9H7O 
C9H9 
-0.06 
0.19 
2b 6-MAPB AC 
 
 
 
 
 
13.0 
MS1 PM at m/z 232.1321 232.1332 C14H18NO2 -4.76 
MS2 fragment ion at m/z 159.0805 
fragment ion at m/z 190.1228 
159.0804 
190.1226 
C11H11O 
C12H16NO 
0.24 
0.88 
MS3 on 159 fragment ion at m/z 131.0491 
fragment ion at m/z 117.0699 
 
131.0491 
117.0698 
 
C9H7O 
C9H9 
 
-0.06 
0.07 
 
MS3 on 190 fragment ion at m/z 159.0803 
fragment ion at m/z 131.0488 
 
159.0804 
131.0491 
 
C11H11O 
C9H7O 
 
-0.65 
-2.85 
 
4 6-APB-M (hydroxy-) 2AC 
6-MAPB-M (N-demethyl-hydroxy-) 2AC 
 
 
 
 
 
 
10.0 
MS1 PM at m/z 276.1223 276.1230 C15H18NO4 -2.51 
MS2 fragment ion at m/z 217.0860 
fragment ion at m/z 234.1126 
217.0859 
234.1124 
C13H13O3 
C13H16NO3 
0.15 
0.40 
MS3 on 217 fragment ion at m/z 189.0548 
fragment ion at m/z 175.0755 
 
189.0546 
175.0753 
 
C11H9O3 
C11H11O2 
 
1.16 
0.99 
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MS3 on 234 fragment ion at m/z 189.0548 
fragment ion at m/z 175.0754 
 
189.0546 
175.0753 
 
C11H9O3 
C11H11O2 
 
0.75 
0.30 
5 6-APB-M (4-carboxymethyl-3-hydroxy amphetamine) ME2AC 
6-MAPB-M (N-demethyl-4-carboxymethyl-3-hydroxy methamphetamine) ME2AC 
 
 
 
 
 
 
9.6 
MS1 PM at m/z 308.1480 308.1492 C16H22NO5 -4.02 
MS2 fragment ion at m/z 266.1385 
fragment ion at m/z 234.1125 
266.1386 
234.1124 
C14H20NO4 
C13H16NO3 
-0.50 
0.32 
MS3 on 266 fragment ion at m/z 234.1127 
fragment ion at m/z 224.1286 
 
234.1124 
224.1281 
 
C13H16NO3 
C12H18NO3 
 
1.05 
2.21 
 
MS3 on 234 fragment ion at m/z 192.1014 
fragment ion at m/z 175.0755 
 
192.1019 
175.0753 
C11H14NO2 
C11H11O2 
 
-2.81 
1.08 
6 6-MAPB-M (hydroxy-) 2AC  
 
 
 
 
 
12.7 
MS1 PM at m/z 290.1376 290.1386 C16H20NO4 -3.63 
MS2 fragment ion at m/z 248.1282 
fragment ion at m/z 217.0860 
248.1281 
217.0859 
C14H18NO3 
C13H13O3 
0.31 
0.39 
MS3 on 248 fragment ion at m/z 217.0858 
fragment ion at m/z 175.0754 
 
217.0859 
175.0753 
 
C13H13O3 
C11H11O2 
 
-0.55 
0.04 
 
MS3 on 217 fragment ion at m/z 175.0754 
fragment ion at m/z 189.0547 
 
175.0753 
189.0546 
C11H11O2 
C11H9O3 
 
0.21 
0.19 
7 6-APB-M (4-hydroxyethyl-3-hydroxy amphetamine) 3AC 
6-MAPB-M (N-demethyl-4-hydroxyethyl-3-hydroxy methamphetamine) 3AC 
 
 
 
 
 
11.3 
MS1 PM at m/z 322.1639 322.1648 C17H24NO5 -2.97 
MS2 fragment ion at m/z 280.1543 
fragment ion at m/z 220.1335 
280.1543 
220.1332 
C15H22NO4 
C13H18NO2 
-0.25 
1.20 
MS3 on 280 fragment ion at m/z 220.1333 
fragment ion at m/z 238.1438 
220.1332 
238.1437 
 
C13H18NO2 
C13H20NO3 
 
0.57 
0.24 
 
MS3 on 220 fragment ion at m/z 161.0961 
fragment ion at m/z 178.1227 
 
161.0960 
178.1226 
 
C11H13O 
C11H16NO 
 
0.05 
0.05 
8 6-MAPB-M (4-carboxymethyl-3-hydroxy methamphetamine) ME2AC 
 
 
 
 
 
11.6 
MS1 PM at m/z 322.1637 322.1648 C17H24NO5 -3.81 
MS2 fragment ion at m/z 280.1543 
fragment ion at m/z 238.1441 
280.1543 
238.1437 
C15H22NO4 
C13H20NO3 
-0.05 
1.40 
MS3 on 280 fragment ion at m/z 238.1437 
fragment ion at m/z 207.1016 
 
238.1437 
207.1015 
 
C13H20NO3 
C12H15O3 
 
-0.26 
0.10 
 
MS3 on 238 fragment ion at m/z 207.1015 
 
207.1015 
 
C12H15O3 
 
-0.55 
9 6-MAPB-M (4-hydroxyethyl-3-hydroxy methamphetamine ) 3AC  
 
 
 
 
12.9 
MS1 PM at m/z 336.1794 336.1805 C18H26NO5 -3.58 
MS2 fragment ion at m/z 294.1699 
fragment ion at m/z 252.1594 
294.1699 
252.1594 
C16H24NO4 
C14H22NO3  
-0.31 
-0.13 
MS3 on 294 fragment ion at m/z 252.1593 
fragment ion at m/z 161.0960 
 
252.1594 
161.0960 
 
C14H22NO3  
C11H13O  
 
-0.28 
-0.13 
 
MS3 on 252 fragment ion at m/z 179.1065 
fragment ion at m/z 161.0959 
 
179.1066 
161.0960 
C11H15O2 
C11H13O 
-0.66 
-0.89 
10 6-APB-M (4-dihydroxyethyl-3-hydroxy amphetamine) 4AC  
6-MAPB-M (N-demethyl-4-dihydroxyethyl-3-hydroxy methamphetamine) 4AC  
 
 
 
 
 
11.2 
MS1 PM at m/z 380.1691 380.1703 C19H26NO7 -3.36 
MS2 fragment ion at m/z 320.1491 
fragment ion at m/z 278.1378 
320.1492 
278.1386 
C17H22NO5 
C15H20NO4 
-0.49 
-3.01 
MS3 on 320 fragment ion at m/z 278.1385 
fragment ion at m/z 236.1281 
 
278.1386 
236.1281 
 
C15H20NO4 
C13H18NO3 
 
-0.59 
0.09 
 
11 6-MAPB-M (dihydro-) AC 
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MS1 PM at m/z 234.1484 234.1488 C14H20NO2 -1.98  
11.7 MS2 fragment ion at m/z 161.0960 
fragment ion at m/z 133.0648 
161.0960 
133.0647 
C11H13O 
C9H9O 
-0.07 
0.18 
MS3 n.d. 
 
   
12 6-APB-M (hydroxy-dihydro-) 2AC 
6-MAPB-M (N-demethyl-hydroxy-dihydro-) 2AC 
 
 
 
 
 
11.3 
MS1 PM at m/z 278.1378 278.1386 C15H20NO4 -3.21 
MS2 fragment ion at m/z 236.1280 
fragment ion at m/z 218.1174 
236.1281 
218.1175 
C13H18NO3 
C13H16NO2 
-0.69 
-0.60 
MS3 on 236 fragment ion at m/z 159.0803 
fragment ion at m/z 177.0909 
 
159.0804 
177.0910 
 
C11H11O 
C11H13O2 
 
-0.74 
-0.70 
 
13 6-MAPB-M (4-dihydroxyethyl-3-hydroxy methamphetamine) 4AC  
 
 
 
 
 
12.9 
MS1 PM at m/z 394.1846 394.1860 C20H28NO7 -3.62 
MS2 fragment ion at m/z 334.1645 
fragment ion at m/z 292.1540 
334.1648 
292.1543 
C18H24NO5 
C16H22NO4 
-1.16 
-0.98 
MS3 on 334 fragment ion at m/z 292.1539 
fragment ion at m/z 261.1119 
 
292.1543 
261.1121 
 
C16H22NO4 
C15H17O4 
 
-1.38 
-0.87 
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Table 2 List of all detected phase II metabolites for 6-APB and 6-MAPB together with the 
masses of their PM recorded in MS1, the corresponding main fragment ions in MS2, the exact 
masses, the corresponding elemental composition, and the deviation of the measured from the 
calculated masses, given as errors in ppm 
 
No. Metabolites and characteristic ions  
Measured accurate masses [u] 
 
Calculated exact 
masses [u] 
Elemental composition 
 
Error 
[ppm] 
RT 
[min] 
4G 6-APB-M (hydroxy-aryl glucuronide) 
 
 
 
 
3.9 
MS1 PM at m/z 368.1348 368.1339 C17H22NO8 2.19 
MS2 fragment ion at m/z 175.0749 
fragment ion at m/z 192.1014 
 
175.0753 
192.1019 
C11H11O2 
C11H14NO2 
-2.66 
-2.49 
5G 6-APB-M (4-carboxymethyl-3-hydroxy amphetamine glucuronide) 
6-MAPB-M (N-demethyl-4-carboxymethyl-3-hydroxy amphetamine glucuronide) 
 
 
 
 
3.2 MS1 PM at m/z 386.1430 386.1445 C17H24NO9 -4.11 
MS2 fragment ion at m/z 210.1120 
fragment ion at m/z 193.0854 
 
210.1124 
193.0859 
C11H16NO3 
C11H13O3 
-2.37 
-2.54 
7G 6-APB-M (4-hydroxyethyl-3-hydroxy amphetamine glucuronide) 
6-MAPB-M (N-demethyl-4-hydroxyethyl-3-hydroxy methamphetamine glucuronide) 
 
 
 
 
2.8 MS1 PM at m/z 372.1636 372.1652 C17H26NO8 -4.28 
MS2 fragment ion at m/z 196.1327  
fragment ion at m/z 179.1062 
196.1332 
179.1066 
 
C11H18NO2 
C11H15O2 
 
-2.39 
-2.62 
8G 6-MAPB-M (4-carboxymethyl-3-hydroxy methamphetamine glucuronide) 
 
 
 
 
2.7 
MS1 PM at m/z 400.1595 400.1602 C18H26NO9 -1.71 
MS2 fragment ion at m/z 224.1276 
fragment ion at m/z 206.1171 
 
224.1281 
206.1175 
C12H18NO3 
C12H16NO2 
-2.90 
-2.06 
9G 6-MAPB-M (4-hydroxyethyl-3-hydroxy methamphetamine glucuronide) 
 
 
 
 
3.8 
MS1 PM at m/z 386.1793 386.1809 C18H28NO8 -4.12 
MS2 fragment ion at m/z 210.1484 
fragment ion at m/z 179.1062 
 
210.1488 
179.1066 
C12H20NO2 
C11H15O2 
-2.26 
-2.54 
10G 6-APB-M (4-dihydroxyethyl-3-hydroxy amphetamine glucuronide) 
6-MAPB-M (N-demethyl-4-dihydroxyethyl-3-hydroxy methamphetamine glucuronide) 
 
 
 
 
4.7 MS1 PM at m/z 388.1602 388.1602 C17H26NO9 0.02 
MS2 fragment ion at m/z 177.0905 
fragment ion at m/z 195.1010 
 
177.0910 
195.1015 
C11H13O2 
C11H15O3 
-2.94 
-2.78 
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Table 3 List of all detected phase metabolites for 6-APB and 6-MAPB in the low dose rat 
urine with the LC-MSn SUSA together with the masses of their precursor ions, the 
corresponding main fragment ions in MS2 and MS3 
 
No. Compounds Precursor ions (m/z) 
MS2 spectra ions (m/z) 
and their relative 
abundances (%) 
MS3 spectra ions in bold 
(m/z) and their relative 
abundance (%) 
1 6-APB N-demethyl 6-MAPB 176 131 (100), 159 (1), 117 (1) 
131: n.d. 
159: n.d. 
2 6-MAPB 190 159 (100), 131 (2) 159: 131 (100), 117 (2) 131: n.d. 
5 
6-APB-M (4-carboxymethyl-3-hydroxy amphetamine) 
6-MAPB-M (N-demethyl-4-carboxymethyl-3-hydroxy 
methamphetamine) 
210 165 (100), 147 (45), 175 (20), 193 (3) 
165: 121 (100), 77 (5) 
147: 119 (100), 91 (20) 
8 6-MAPB-M (4-carboxymethyl-3-hydroxy methamphetamine) 224 
193 (100), 165 (20), 147 
(10), 175 (5) 
193: 165 (100), 147 (50) 
165: 121 (100) 
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Legends to Figures 
 
Fig. 1 EI mass spectra, gas chromatographic retention indices (RI), proposed structures, and 
predominant fragmentation patterns of acetylated 6-APB (1) and 6-MAPB (2) and their 
metabolites (3 - 10) arranged according to their RI 
 
Fig. 2 Proposed metabolic pathways for 6-APB and 6-MAPB in rat 
 
Fig. 3 Reconstructed ion chromatograms with the given ions from rat urines after a low dose 
of 6-APB (A) and 6-MAPB (B) after acid hydrolysis, liquid-liquid extraction and acetylation 
and analysis with the GC-MS standard urine screening approach SUSA and after protein 
precipitation of those urines (C-D) and analysis with the LC-MSn SUSA 
 
Fig. 4 Reconstructed ion chromatograms with the given ions of a reference compound 
mixture of 5-APB, 6-APB, 5-MAPB, and 6-MAPB after heptafluorobutyrylation (A), or of a 
mixture of low dose rat urine samples after conjugates cleavage, solid phase extraction, and 
heptafluorobutyrylation (B), structures, proposed fragmentation patterns, and corresponding 
EI mass spectra (C) 
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Fig. 1 EI mass spectra, gas chromatographic retention indices (RI), proposed structures, and predominant 
fragmentation patterns of acetylated 6-APB (1) and 6-MAPB (2) and their metabolites (3 - 10) arranged 
according to their RI  
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Fig. 1 continued  
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Fig. 2 Proposed metabolic pathways for 6-APB and 6-MAPB in rat  
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Fig. 3 Reconstructed ion chromatograms with the given ions from rat urines after a low dose of 6-APB (A) 
and 6-MAPB (B) after acid hydrolysis, liquid-liquid extraction and acetylation and analysis with the GC-MS 
standard urine screening approach SUSA and after protein precipitation of those urines (C-D) and analysis 
with the LC-MSn SUSA  
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Fig. 4 Reconstructed ion chromatograms with the given ions of a reference compound mixture of 5-APB, 6-
APB, 5-MAPB, and 6-MAPB after heptafluorobutyrylation (A), or of a mixture of low dose rat urine samples 
after conjugates cleavage, solid phase extraction, and heptafluorobutyrylation (B), structures, proposed 
fragmentation patterns, and corresponding EI mass spectra (C)  
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